<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742440</url>
  </required_header>
  <id_info>
    <org_study_id>022018-035</org_study_id>
    <nct_id>NCT03742440</nct_id>
  </id_info>
  <brief_title>GrafixPL PRIME Evaluation Case Study</brief_title>
  <official_title>GrafixPL PRIME Evaluation Case Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osiris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40)&#xD;
      that receive optimal treatment including serial wound debridement and off-loading with total&#xD;
      contact casts or a boot and GrafixPL PRIME. In addition, the investigators will collect data&#xD;
      on other potential confounding factors that could affect healing such as medications,&#xD;
      tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity.&#xD;
      Wound healing, including wound size and adverse events will be evaluated. The objective of&#xD;
      this study is to understand the use of this product to evaluate wound healing in 40 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening and Enrollment:&#xD;
&#xD;
        -  Review and sign the Informed Consent and HIPAA Authorization&#xD;
&#xD;
        -  Review the inclusion and exclusion criteria&#xD;
&#xD;
      If the subject qualifies for the study, they will participate in the following procedures&#xD;
      (weekly visits, +/-4 days):&#xD;
&#xD;
      Visit 0:&#xD;
&#xD;
        -  Demographics (such as age, gender, race or ethnicity)&#xD;
&#xD;
        -  Medical/Surgical and Social History, Current Antibiotics.&#xD;
&#xD;
        -  Laboratory Results&#xD;
&#xD;
        -  Vascular - ABI&#xD;
&#xD;
        -  Neurological evaluation - Monofilament and VPT&#xD;
&#xD;
        -  Vitals - Sitting blood pressure and Pulse rate, Height/Weight, and BMI&#xD;
&#xD;
        -  Wound debridement&#xD;
&#xD;
        -  eKare - Wound imaging measurement&#xD;
&#xD;
        -  Application of GrafixPL PRIME&#xD;
&#xD;
        -  Current Antibiotics&#xD;
&#xD;
        -  Offloading&#xD;
&#xD;
        -  Adverse Events&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
      Visits 1 - 11:&#xD;
&#xD;
        -  Wound debridement&#xD;
&#xD;
        -  eKare - Wound imaging measurement&#xD;
&#xD;
        -  Application of GrafixPL PRIME&#xD;
&#xD;
        -  Current Antibiotics&#xD;
&#xD;
        -  Offloading&#xD;
&#xD;
        -  Adverse Events&#xD;
&#xD;
        -  Source documentation&#xD;
&#xD;
      Visit 12/End of Study (EOS) Visit:&#xD;
&#xD;
        -  Wound debridement&#xD;
&#xD;
        -  eKare - Wound imaging measurement&#xD;
&#xD;
        -  Current Antibiotics&#xD;
&#xD;
        -  Offloading&#xD;
&#xD;
        -  Adverse Events&#xD;
&#xD;
        -  Source documentation (End of Study will occur on the date the subject is healed)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Closure of the Index Ulcer</measure>
    <time_frame>12 weeks</time_frame>
    <description>Complete closure of the index ulcer, defined as 100% re-epithelialization as determined by the Investigator by week 12 or the End of Treatment Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Closure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>There was no control arm in this study - everyone enrolled received treatment. Analysis of these data was separated into two groups - &quot;closed wounds&quot; and &quot;not closed wounds.&quot; Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>GrafixPL PRIME</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GrafixPL PRIME</intervention_name>
    <description>GrafixPL PRIME</description>
    <arm_group_label>GrafixPL PRIME</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  18-90 years of age&#xD;
&#xD;
          -  Chronic foot ulceration below the ankle - persistent for 30 days or longer&#xD;
&#xD;
          -  Ankle Brachial Index (ABI) &gt;0.5 (Bedside ABI is acceptable for screening purposes as&#xD;
             the formal imaging ABI may not be resulted prior to surgery)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  &lt;18 or &gt;90 years of age&#xD;
&#xD;
          -  History of poor compliance with follow-up visits&#xD;
&#xD;
          -  Gangrene&#xD;
&#xD;
          -  Untreated Osteomyelitis&#xD;
&#xD;
          -  Widespread malignancy&#xD;
&#xD;
          -  Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines&#xD;
&#xD;
          -  Currently Pregnant or planning pregnancy during the course of intended participation&#xD;
             in the study&#xD;
&#xD;
          -  Is nursing or actively lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Lavery, DPM MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <results_first_submitted>July 13, 2020</results_first_submitted>
  <results_first_submitted_qc>July 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2020</results_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Larry Lavery</investigator_full_name>
    <investigator_title>Professor and Director of Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03742440/Prot_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GrafixPL PRIME</title>
          <description>Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.&#xD;
GrafixPL PRIME: GrafixPL PRIME</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GrafixPL PRIME</title>
          <description>Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.&#xD;
GrafixPL PRIME: GrafixPL PRIME</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>feet</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Age of All Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Closure of the Index Ulcer</title>
        <description>Complete closure of the index ulcer, defined as 100% re-epithelialization as determined by the Investigator by week 12 or the End of Treatment Visit.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GrafixPL PRIME</title>
            <description>Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.&#xD;
GrafixPL PRIME: GrafixPL PRIME</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Closure of the Index Ulcer</title>
          <description>Complete closure of the index ulcer, defined as 100% re-epithelialization as determined by the Investigator by week 12 or the End of Treatment Visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Closure</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GrafixPL PRIME</title>
            <description>Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.&#xD;
GrafixPL PRIME: GrafixPL PRIME</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Closure</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Adverse Events</title>
        <description>There was no control arm in this study - everyone enrolled received treatment. Analysis of these data was separated into two groups - &quot;closed wounds&quot; and &quot;not closed wounds.&quot; Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.</description>
        <time_frame>12 weeks</time_frame>
        <population>There was no control arm in this study. Analysis of these data was separated into two groups - &quot;closed wounds&quot; and &quot;not closed wounds.&quot; Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>GrafixPL PRIME</title>
            <description>Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.&#xD;
GrafixPL PRIME: GrafixPL PRIME</description>
          </group>
        </group_list>
        <measure>
          <title>Total Adverse Events</title>
          <description>There was no control arm in this study - everyone enrolled received treatment. Analysis of these data was separated into two groups - &quot;closed wounds&quot; and &quot;not closed wounds.&quot; Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.</description>
          <population>There was no control arm in this study. Analysis of these data was separated into two groups - &quot;closed wounds&quot; and &quot;not closed wounds.&quot; Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.</population>
          <units>number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Closed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not closed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks of weekly visits</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GrafixPL PRIME</title>
          <description>Open-label case series to evaluate GrafixPL PRIME. All subjects received the product.&#xD;
GrafixPL PRIME: GrafixPL PRIME</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Non-foot related hospitalization</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for foot-related issue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>All adverse events</sub_title>
                <description>Includes all reinfections of the foot, pneumonia, antibiotics for any reason not including foot infection, and cutaneous abscess on non-study limb.</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence Lavery, DPM, MPH</name_or_title>
      <organization>UT Southwestern Medical Center at Dallas</organization>
      <phone>214-645-0544</phone>
      <email>Larry.Lavery@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

